Primary immunodeficiency diseases (PIDs) — SCID, XLA, CVID, CGD

What changes during this transition

Primary immunodeficiency diseases are the family of inborn errors of immunity — over 450 syndromes recognized in the IUIS 2022 classification with the 2024 update extending the count further. The clinical population is heterogeneous, pediatric-onset-skewed, and lifelong-management-anchored. The four patient-community-organized syndromes load-bearing for this substrate are SCID, XLA, CVID, and CGD; the broader 'other PIDs' family (Wiskott-Aldrich, Ataxia-telangiectasia, DiGeorge, Hyper-IgM, IPEX, X-linked lymphoproliferative, STAT/JAK signaling defects) is covered editorially because framing about community peptides is consistent across the inherited-immune-defect class. SCID — 'bubble baby disease' — is multiple genetic etiologies converging on the same lethal phenotype: T-cell plus B-cell plus NK-cell deficiency with infant presentation and fatal infections in the first year of life without treatment. The diagnostic landscape was transformed by TREC newborn screening (US RUSP 2010, universal by 2018): early-life diagnosis catches SCID before the first fatal infection, allogeneic HSCT performed in the first 3-4 months with a matched sibling donor produces dramatically better outcomes than rescue transplantation in older symptomatic infants. STRIMVELIS (GSK) — the first ex vivo gene therapy approved for any disease in the EU (EMA 2016) — exists as an alternative pathway for ADA-SCID, and ELAPEGADEMASE (Revcovi, Leadiant Biosciences) is a pegylated recombinant ADA enzyme replacement FDA-approved October 2018 as weekly subcutaneous injection. Gene therapy programs for X-SCID (Genethon, Mustang Bio MB-107) are advancing. XLA is caused by BTK mutations producing B-cell developmental arrest and male-predominant presentation at 6-12 months with recurrent encapsulated bacterial infections. Standard-of-care is IVIG monthly or SCIg weekly LIFELONG. CVID is the most common symptomatic PID in adult-onset population — heterogeneous, with ~25% identifiable monogenic cause (TACI, ICOS, NFKB1/2, CTLA4, LRBA), hypogammaglobulinemia + poor vaccine response + recurrent infections + autoimmunity + granulomatous disease + lymphoid malignancy risk. IgG replacement lifelong; ABATACEPT (Orencia, BMS) for CTLA4 deficiency; rapamycin for LRBA; HSCT for severe refractory cases. CGD is caused by NADPH oxidase complex defects (CYBB X-linked most common; NCF1, NCF2, NCF4, CYBA recessive) producing characteristic susceptibility to catalase-positive bacterial and fungal infections (Aspergillus, Staph aureus, Burkholderia cepacia, Nocardia, Serratia). Prophylactic TMP-SMX + itraconazole + IFN-gamma (Actimmune, Horizon Therapeutics — FDA-approved 1990, one of the earliest cytokine therapies); HSCT curative; Orchard Therapeutics OTL-102 lentiviral gene therapy investigational. Multi-jurisdictional reality: the Strimvelis EMA 2016 approval preceded the US ADA-SCID enzyme replacement approval (Revcovi October 2018), Europe leading on cell and gene therapy. Immune Deficiency Foundation (IDF, primaryimmune.org), Jeffrey Modell Foundation (JMF, info4pi.org), European Society for Immunodeficiencies (ESID), USIDNET — the multi-jurisdictional registry infrastructure is the standard-of-care backbone. No peptide in the Juno library has a discovery-card-defensible PID case. BPC-157 reaches the population through 'immune modulation' and 'gut healing' framing — both mechanistic collisions with inherited immune defect biology. Patients on IgG replacement therapy already carry a SC injection regimen (SCIg weekly or IVIG monthly through PICC), and stacking a community SC peptide creates injection-site-reaction overlap, scheduling conflicts, and an uncharacterized pro-angiogenic VEGF / NO mechanism. NMN reaches the population through the general-aging channel in adult-onset CVID and aging XLA-survivor cohort. The GH-axis trio (CJC-1295 + ipamorelin + tesamorelin) surfaces the pediatric PID growth-velocity question — disease control via standard-of-care is the lever, and somatropin under specialist supervision is the established replacement if confirmed GHD layers on PID; tesamorelin Rule 6 non-propagation is sharpest. Semaglutide is the coordination-of-care conversation with PID-emergency frame overlay. Ninety-first deliberate non-elevation.